GLOBAL DEVELOPMENTS AND TRENDS
The road to Gavi’s 2020 Replenishment

- **Jan. 2015**
  Gavi Pledging Conference
  Berlin

- **Aug. 2019**
  Gavi Investment Launch
  TICAD
  Japan

- **9-11 Dec. 2018**
  Gavi Mid-Term Review
  Abu Dhabi

- **Jun. 2019**
  Gavi 5.0 Strategic Framework

- **Mid-2020**
  Gavi Pledging Conference
  London

- **Jan. 2020**
  Gavi 20th Anniversary
  Davos
The road to Gavi’s 2020 Replenishment

- Jan. 2015: Gavi Pledging Conference, Berlin
- Sept. 2019: UNGA, New York
- Aug. 2019: Gavi Investment Launch, TICAD, Japan
- Nov. 2018: Global Financing Facility Replenishment, Oslo
- 9-11 Dec. 2018: Gavi Mid-Term Review, Abu Dhabi
- Jun. 2019: Gavi 5.0 Strategic Framework
- Jan. 2020: Gavi 20th Anniversary, Davos
Focus on PHC, including launch of universal knowledge initiative

Vaccine hesitancy as a global problem

Concerns on Global Health Security

North-South, South-North learning
Collaboration with partners
Collaboration with partners

Core Alliance partners

Gavi
The Vaccine Alliance

The Global Fund

UNAIDS

UNDP
Empowered lives. Resilient nations.

UN Women

UNITAID

World Bank Group

WFP
World Food Programme

WHO
World Health Organization
Collaboration with partners

Co-leading GAP Financing Accelerator
Collaboration with partners

Malaria vaccine pilots
Collaboration with partners

Gavi
The Vaccine Alliance

The Global Fund

Global Financing Facility

UNAIDS

UNDP
Empowered lives. Resilient nations.

UNFPA

HPV vaccine

unicef

Unitaid

UN Women

World Bank Group

WFP
World Food Programme

World Health Organization
Collaboration with partners

TOWARDS A GLOBAL ACTION PLAN FOR HEALTHY LIVES AND WELL-BEING FOR ALL

Uniting to accelerate progress towards the health-related SDGs

A joint initiative of:

- Gavi
- The Global Fund
- Unitaid
- Unicef
- UNAIDS
- UN Women
- World Bank Group
- WFP
- World Health Organization

National collaborations
WHO reform

10 April 2019, Stockholm, Sweden, Inaugural WHO Partners Forum
WHO reform

- Major structural and personnel changes
- Complex implementation including down through organisation

->Significant changes in leadership on immunisation and primary health
WHO reform

- Major structural and personnel changes
- Complex implementation including down through organisation

-> Significant changes in leadership on immunisation and primary health

“Most significant reform in 71-year-history”
- Dr Tedros
Antimicrobial resistance

UN Interagency Coordination Group (IACG) on Antimicrobial Resistance report recognises critical role of vaccines

“A sustained effort is needed to spur increased innovation in medicines, diagnostics, vaccines and safe and effective alternatives to antimicrobials…”

Credit: Office of the UN Secretary-General
Growing health impact of climate change

- *Aedes aegypti* mosquitoes continues to extend its range north
- Mosquito vector of yellow fever, Dengue, Zika, Chikungunya viruses
- 900 million more people at risk of infection by 2080

![Map showing current and predicted range of *Aedes aegypti* mosquitoes.]

Growing health impact of climate change

- Cyclone Idai, third worst in history, devastated Mozambique, Malawi and Zimbabwe:
  - >1000 killed
  - ~ USD 2 billion damages
  - Cholera outbreaks

- Cyclone Kenneth subsequently hits disaster-stricken Mozambique

- Such events may become the ‘new normal’
2. REPORTING BACK
Oral cholera vaccine (OCV)

- Gavi funded ~900,000 doses and operational costs to respond to cholera outbreak after Cyclone Idai.
- Rapid decline in cases demonstrates impact of OCV.
- Continued growth in use of OCV stockpile globally in 2019:
  - Cameroon
  - DRC
  - Ethiopia
  - Nigeria
  - Somalia
  - Zambia
  - Zimbabwe

Cholera cases in Sofala Province, Mozambique post Cyclone Idai.
Ebola escalating in DRC

- Second largest Ebola outbreak in history

Source: WHO SitRep (24 June 2019)
Ebola escalating in DRC

- Second largest Ebola outbreak in history
- >2,200 cases and >1,500 deaths in DRC – continued spread

Source: WHO SitRep (24 June 2019)
Ebola escalating in DRC

- Second largest Ebola outbreak in history

- >2,200 cases and >1,500 deaths in DRC – continued spread

- 16 health zones (districts) have notified at least one EVD confirmed case over the last 21 days

*Source: WHO SitRep (24 June 2019)*
Ebola escalating in DRC

- **Second largest Ebola outbreak** in history

- >2,200 cases and >1,500 **deaths** in DRC – continued spread

- **16 health zones** (districts) have notified at least one EVD confirmed case over the last 21 days

- **First cross-border infections** with 3 deaths in Uganda but not yet public health emergency of international concern

*Source: WHO SitRep (24 June 2019)*
Ebola escalating in DRC

- Second largest Ebola outbreak in history
- >2,200 cases and >1,500 deaths in DRC – continued spread
- 16 health zones (districts) have notified at least one EVD confirmed case over the last 21 days
- First cross-border infections with 3 deaths in Uganda but not yet public health emergency of international concern

Source: WHO SitRep (24 June 2019)
Vaccines critical part of Ebola response

- >135,000 people vaccinated in DRC. Challenges of violence and community distrust
  - Ebola vaccine available in part due to Advanced Purchase Commitment
  - Gavi provided >$15M in operational support

- 5,000 high-risk frontline individuals already received preventive vaccination in Uganda (165 clinics).
  - 2,500 in South Sudan and 1,400 in Rwanda
  - Burundi to start shortly

- In response to recent spread to Uganda, outbreak vaccination initiated with ~3,400 doses sent from DRC
Ebola vaccine efficacy confirmed

- Data from Equateur and North Kivu Ebola immunisation (DRC) indicates 97.5% efficacy of vaccine – confirming results of 2015 Guinea trial

- WHO Strategic Advisory Group of Experts on Immunisation recommends adjusted dosing

- >250,000 doses (1 ml) available for shipment; more vaccine expected over the coming year
DRC: Early progress in efforts to strengthen routine immunisation

- Latest survey shows coverage <50%
- With Alliance support, Minister of Health has devised ‘Mashako Plan’ to raise coverage
- Initial focus on nine provinces – to be expanded through next HSS

**Supervision**

Supervisions des centres de santé dans 9 provinces

<table>
<thead>
<tr>
<th></th>
<th>dec</th>
<th>jan</th>
<th>fev</th>
<th>Mar</th>
<th>Avril</th>
<th>Mai</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>15%</td>
<td>30%</td>
<td>44%</td>
<td>55%</td>
<td>59%</td>
<td>69%</td>
</tr>
</tbody>
</table>

**Sessions**

% d’aires supervisées respectant le minimum de séances à organiser

<table>
<thead>
<tr>
<th></th>
<th>Décembre</th>
<th>Janvier</th>
<th>Février</th>
<th>Mars</th>
<th>Avril</th>
<th>Mai</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>46%</td>
<td>50%</td>
<td>61%</td>
<td>68%</td>
<td>72%</td>
<td>72%</td>
</tr>
</tbody>
</table>

**Cold chain**

% fonctionnalité de la chaîne du froid

<table>
<thead>
<tr>
<th></th>
<th>Décembre</th>
<th>Janvier</th>
<th>Février</th>
<th>Mars</th>
<th>Avril</th>
<th>Mai</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>41%</td>
<td>73%</td>
<td>81%</td>
<td>85%</td>
<td>87%</td>
<td>90%</td>
</tr>
</tbody>
</table>

Note: December represents partial data as monitoring app not yet fully deployed.
Global resurgence of measles

- Since January 2018, 47 of 53 (WHO) European countries
- Measles again endemic in all 6 WHO regions

300% increase globally in Q1 2019
Vaccine hesitancy

Low trust in vaccines ‘a global crisis’

Hesitancy now among top 10 global health threats, says WHO
Vaccine hesitancy

Low trust in vaccines ‘a global crisis’

Hesitancy now among top 10 global health threats, says WHO

Globally, around eight in 10 people agree vaccines are safe, and nine in 10 people worldwide say their children have been vaccinated
Vaccine hesitancy

- Social media enables misinformation to spread rapidly and broadly

- Gavi increasingly engaged:
  - Wrote to 11 digital and social media platform CEOs requesting response
  - Op-ed co-authored with Congress Rep. Dr. Ami Bera, Chair of Oversight and Investigations Subcommittee of the House Foreign Affairs Committee, highlighting problem

- Twitter, Instagram and others beginning to take action – e.g., banning anti-vax hashtags, redirecting traffic to trusted sites
Polio eradication status

• 34 wild polio cases to date this year, compared to 33 in whole of 2018 – 26 in Pakistan alone (vs. 3 in all of 2018)

• Vaccine-derived polio cases in seven countries already in 2019:
  • Angola
  • Central African Republic
  • DR Congo
  • Ethiopia
  • Niger
  • Nigeria
  • Somalia

• Growing Gavi-GPEI collaboration to strengthen routine immunisation

• Gavi CEO now on Polio Oversight Board

Source: GPEI, 22 June 2019
Typhoid Conjugate Vaccine (TCV)

First data from large-scale TCV efficacy trial

• Interim analysis from site in Nepal estimated 82% vaccine efficacy

• Bangladesh and Malawi data available in 6-12 months

Initial roll-out of TCV with Gavi support - strong demand

• Zimbabwe - First Gavi-supported non-trial TCV use in Africa. 325,000 people vaccinated in response to outbreak in Harare

• Pakistan - large outbreak of extremely drug-resistant disease; first Gavi-supported routine TCV introduction – phase 1 scheduled for Q4 in 2019

Credit: Sam Reinders / Gavi
Malaria pilots launched

• First pilots of RTS,S malaria vaccine launched in Malawi and Ghana; Kenya launching soon

• Will test impact, cost-effectiveness and safety in real-world setting, and feasibility of 4-dose schedule

• Data will inform initial WHO policy recommendation on broader use of RTS,S/AS01 as early as 2021 based on safety data

• Board to decide on funding for second phase in December
HPV supply constraints continue to delay vaccine scale-up

Demand forecast at time of December 2016 board decision
Routine
Multi-Age Cohort

Latest supply forecast

Million doses

2018  2019  2020
Nigeria: Progress

• **Accountability Framework signed** by Ministers of Health, Finance, and Budget and Planning

• **Applications approved** for measles second dose; yellow fever, Meningitis A and measles campaigns; HSS phase I and CCEOP

• Survey data shows **rise in Penta 3 coverage**, from 33% (MICS/NICS 2016) to 50.9% (DHS 2018)
Syrian Arab Republic now Gavi-eligible

- Continued crisis
  - 5.6M children need humanitarian assistance; ~0.5 M in hard-to-reach camps
  - UNHCR report (2019): Syria single largest source of refugees – 6.7 million of 70 million worldwide

- Through Gavi support, partners aimed to vaccinate ~3M children (<5y) in Syria during World Immunisation Week in end April 2019

- Complex negotiations with the Government on future support
Sudan: success at risk?

- High-performing country, with DTP3 coverage rising from 62% in 2000 to 95% in 2017

- Was on track for transition in 2025 but political unrest and violence may put performance at risk
Vaccine introductions

20 vaccine introductions to date in 2019
Vaccine introductions

- Typhoid
- Pneumococcal
- Rotavirus
- Measles
- Meningitis A
- Measles-rubella
- Human papillovirus
- Japanese encephalitis
- Inactivated polio
- Yellow fever

20 vaccine introductions to date in 2019

Bhutan – PCV introduced post-transition with catalytic support
Vaccine introductions

~35 vaccine introductions to follow in 2019
All 73 Gavi-supported countries now introduced IPV

Mongolia and Zimbabwe introduced IPV 2019
• 50% increase in number of children immunised with DTP3 since 2000, and a 40% reduction in number of under-immunised despite population growth
Coverage & equity: Reaching more children but struggling to reach zero-dose

- 50% increase in number of children immunised with DTP3 since 2000, and a 40% reduction in number of under-immunised despite population growth

- Number of zero dose stagnant - key challenge for Gavi 5.0
Population growth outpaces vaccine coverage increase: coverage ‘plateau’ in Africa

Target population and vaccinated by WHO region over time

Source: Katherine O’Brien, WHO IVB
HSS disbursements scaling up

HSS disbursements by calendar year
US$ million

2007  92
2008  138
2009  34
2010  50
2011  44
2012  52
2013  119
2014  145
2015  172
2016  194
2017  226
2018  284

>6x
HSS impact in fragile context: Central African Republic

- **New HSS grant began in 2017** with focus on improving service delivery and supervision, supported by increased TCA

- **Strong leadership from Minister** and robust partnership among Alliance partners

- Preliminary survey results indicate improvement in coverage, with admin coverage increasing by **20pp to 74%** between 2017 and 2018

- **Now equipping 50% of facilities with cold chain** to offer regular immunisation services (from 20% equipped today)
Pakistan: Reaching unreached in urban slums

Children in slums are least likely to be immunised

Penta 3 coverage %

<table>
<thead>
<tr>
<th></th>
<th>Punjab</th>
<th>Lahore</th>
<th>Lahore (without slums)</th>
<th>Lahore (only slums)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage</td>
<td>87</td>
<td>77</td>
<td>95</td>
<td>54</td>
</tr>
</tbody>
</table>

*Source: MICS 2018, CHIP Urban Profiling, coverage assessment of Urban Centre 110*

*Credit: Asad Zaidi / GAVI*
Pakistan: Reaching unreached in urban slums

In Lahore, many large, densely populated areas are poorly covered by public facilities.

*Note:* Fixed sites shown on map do not include EPI fixed sites as currently their coordinates are unavailable. *Source:* Roadmap Team analyses, MEA data, Evaccs Dec 2018 data, Landscan.
Pakistan: Reaching unreached in urban slums

In Lahore, many large, densely populated areas are poorly covered by public facilities.

*Note:* Fixed sites shown on map do not include EPI fixed sites as currently their coordinates are unavailable. *Source:* Roadmap Team analyses, MEA data, Evaccs Dec 2018 data, Landscan.
Pakistan: Reaching unreached in urban slums

Example of a poorly-served Urban Centre with a large slum

Note: Fixed sites shown on map do not include EPI fixed sites as currently their coordinates are unavailable. Source: Roadmap Team analyses, MEA data, Evaccs Dec 2018 data, Landscan.
Pakistan: Reaching unreached in urban slums

Lahore: polio case occurs outside served areas

Note: Fixed sites shown on map do not include EPI fixed sites as currently their coordinates are unavailable. Source: Roadmap Team analyses, MEA data, Evaccs Dec 2018 data, Landscan.
Pakistan: Reaching unreached in urban slums

Lahore: polio case occurs outside served areas

(Zoomed)

Date of onset: 17th April 2019

Note: Fixed sites shown on map do not include EPI fixed sites as currently their coordinates are unavailable. Source: Roadmap Team analyses, MEA data, Evaccs Dec 2018 data, Landscan
Pakistan: Reaching unreached in urban slums

Granular micro-plans needed to ensure adequate service delivery and reach the unreached

Example digital map of DG Khan

Source: Roadmap Team analyses, and EPI
Unilever partnership demonstrates importance of demand for C&E

• ‘Successful Start’ partnership to educate parents and make immunisation core component of successful parenting

• Initial roll-out in two low performing districts engaged 44,000 households in two districts (2.4M population)

• Scale-up begins in July to a further 580,000 households in 14 districts (>15M population)
**Unilever partnership demonstrates importance of demand for C&E**

- ‘Successful Start’ partnership to educate parents and make immunisation core component of successful parenting
- Initial roll-out in two low performing districts engaged 44,000 households in two districts (2.4M population)
- Scale-up begins in July to a further 580,000 households in 14 districts (>15M population)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>MV0 (n=480)</th>
<th>MV1 (n=496)</th>
<th>MV2 (n=455)</th>
<th>MV3 (n=440)</th>
<th>MV4 (n=369)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rota</td>
<td>1.2</td>
<td>24.5*</td>
<td>35.7*</td>
<td>70.2*</td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td></td>
<td>45.9</td>
<td>63.1*</td>
<td>69.4*</td>
<td>66.9*</td>
</tr>
<tr>
<td>Pentavalent</td>
<td></td>
<td></td>
<td>66.1</td>
<td>65.7</td>
<td>72.5</td>
</tr>
</tbody>
</table>
Growing use of drones for immunisation

Ghana: Four distribution centres providing vaccines to over 2,000 health facilities over four years; 600 flights a day, operating 24/7 to serve 12 million citizens
# Gavi, the Vaccine Alliance strategy 2021 - 2025

## Vision

**Leaving no-one behind with immunisation**

### Mission 2025

- **Vision 2025**: To save lives and protect people’s health by increasing coverage and equitable use of vaccines

### Mission Indicators

- Child mortality reduction
- Lives saved
- Future DALYs averted
- People (male & female) vaccinated with Gavi support across the life course
- People vaccinated with Gavi support against outbreak-prone diseases
- Economic benefits unlocked

### Principles

- Missed communities, first priority: Prioritise children missing out on vaccination including among migrants, displaced and other vulnerable populations
- Gender focused: Apply a gender lens to removing barriers for immunisation
- Country-led, sustainable: Bolster country leadership to sustainably deliver and finance immunisation
- Community owned: Ensure community trust and confidence in vaccines by engaging communities in planning, implementation and oversight of immunisation
- Differentiated: Target and tailor support to national and subnational needs including fragile contexts

### Goals

1. **INTRODUCE AND SCALE UP VACCINES**

   - A. Strengthen countries’ prioritisation of vaccines appropriate to their context
   - B. Support countries to introduce and scale up coverage of vaccines for prevention of endemic and epidemic diseases
   - C. Enhance outbreak response through availability and strategic allocation of vaccine stockpiles

2. **STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION**

   - A. Help countries extend immunisation services to regularly reach under-immunised and zero-dose children as a platform for stronger primary health care
   - B. Support countries to ensure immunisation services are well-managed, sustainable, harness innovation and meet the needs of all care givers
   - C. Work with countries and communities to build resilient demand, and to leverage gender to address immunisation barriers

3. **IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES**

   - A. Strengthen national and subnational political and social commitment to immunisation
   - B. Promote prioritisation of domestic public resources for immunisation and primary health care to improve allocative efficiency
   - C. Prepare and engage self-financing countries to maintain or increase performance

4. **ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS**

   - A. Ensure sustainable, healthy market dynamics for vaccines and immunisation-related products at affordable prices
   - B. Incentivise innovation for the development of suitable vaccines
   - C. Scale up innovative immunisation-related products

### Enablers

- Secure long-term predictable funding for Gavi programmes
- Ensure global political commitment for immunisation, prevention and primary health care
- Use evidence, evaluations and improved data for policies, programmes and accountability
- Leverage the private sector, including through innovative finance mechanisms and partnerships
Gavi 5.0: the Alliance’s 2021-25 strategy framework

Gavi 4.0 to Gavi 5.0: Key shifts

Leaving no one behind with immunisation

➢ Equity as organising principle – focus on zero-dose children
➢ More differentiated, tailored and targeted support for countries
➢ Enhanced focus on demand, communities and gender
➢ Strengthened approach to programmatic sustainability
➢ More systematic attention to preventing & responding to outbreaks
➢ More deliberate approach to innovation
Gavi 4.0 to 5.0 – Sustained impact in next period

Preliminary impact forecasts, 2021-2025

Maintaining impact despite country transitions:

~300 million Children immunised

~7 million Deaths averted

Newer vaccines preventing more deaths:

30-50% More deaths averted from PCV and rotavirus

Significantly higher impact

From HPV

Source: Gavi Operational Forecast and Vaccine Impact Modeling Consortium
2021-2025 funding scenarios

Total: US$ 9.4-9.7

- **2016–2020 (original Berlin figures)**
  - Vaccines in Berlin investment case spend: US$ 6.48
  - Decrease in vaccines in Berlin investment case spend: US$ 0.03

- **2016–2020 (latest)**
  - Vaccines in Berlin investment case spend: US$ 4.92
  - Decrease in vaccines in Berlin investment case spend: US$ 0.15

- **2021–2025 (forecasted expenditures)**
  - Vaccines in Berlin investment case spend: US$ 4.08
  - Decrease in vaccines in Berlin investment case spend: US$ 0.36

**Total funding requirements (US$ billion)**

- **Prov. for strategic inv. (incl. malaria)**: US$ 0.50
- **Enabling support and business plan**: US$ 2.50
- **IPV**: US$ 3.71
- **“Catalytic vaccines”**: US$ 0.36
- **Ebola**: US$ 0.30
- **VIS**: US$ 0.30
- **Vaccines in Berlin investment case**: US$ 4.08

*Preliminary*
**Gavi 5.0 – Greater outcomes and value for money**

### Preliminary impact forecasts

<table>
<thead>
<tr>
<th>Unique children immunised with Gavi support</th>
<th>Deaths averted by 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2000-2017</strong></td>
<td><strong>2000-2017</strong></td>
</tr>
<tr>
<td>~700 million</td>
<td>10 million</td>
</tr>
<tr>
<td><strong>2018-2025</strong></td>
<td><strong>2018-2025</strong></td>
</tr>
<tr>
<td>&gt;400 million</td>
<td>~12 million</td>
</tr>
</tbody>
</table>

**Total: >1.1 billion**                      **Total: ~22 million**

*Source: Gavi Operational Forecast and Vaccine Impact Modeling Consortium*
Gavi 4.0 evaluations: Learning to inform Gavi 5.0 strategy

- “Review of Gavi’s Performance-Based Funding Component of its Health System Strengthening Support” (September 2018)
- “Measles campaigns and their effects on the overall immunization system” (November 2018)
- “Evaluation of Gavi’s Support to Civil Society Organisations” (November 2018)
- “Review of Health System Strengthening Support” (March 2019)
- “Evaluation of the Cold Chain Equipment Optimization Platform” (April 2019)
- “Evaluation of Gavi’s Gender Policy” (May 2019)
3. ALLIANCE UPDATE
The Islamic Development Bank Group (IsDB) invests US$ 50 million in a Sukuk bond issued by IFFIm aimed at accelerating funding for immunisation efforts.

Norway contributes NOK 600 million to IFFIm to fund CEPI’s development of new vaccines for developing country epidemic diseases.
Changes in partner Board leadership

Shanelle Hall
Former Deputy Executive Director

Omar Abdi
Deputy Executive Director for Programmes
Changes in partner Board leadership

Tim Evans, Senior Director
Health, Nutrition and Population Global Practice

Muhammed Pate
Global Director for Health, Nutrition and Population, and Director of Global Financing Facility
Changes in partner Board leadership

Soumya Swaminathan
Chief Scientist

Peter Salama, Executive Director
Universal Health Coverage/ Life Course
Global Health Campus comes to life
Retirement of long-serving senior staff

Hind Khatib-Othman
MD Country Programmes

Barry Greene
MD Finance & Operations
New Managing Director, Finance and Operations

Assietou Diouf
MD Finance & Operations
New Managing Director, Country Programmes

Thabani Maphosa
MD Country Programmes

Start: 1 September 2019
Updating Secretariat systems

Go live date for ERP phase 1 (SAP S/4HANA for Finance) – Oct. 2019
Multi-year Secretariat effort and investment

Engage a cloud-based finance ERP for the digital age
4.

AGENDA FOR THIS MEETING
Our agenda

Board agenda

1. 2016-2020 Strategy: Progress, Challenges and Risks
2. Replenishment 2020
3. Road to Replenishment
4. Gavi 5.0: The Alliance’s 2021-2025 Strategy
5. Gavi 5.0: Operationalising the Alliance’s 2021-2025 Strategy
6. Review of the Strategy for Papua New Guinea
7. Co-financing arrangements for Inactivated Poliovirus Vaccine (IPV) post 2020
8. Committee Chair and IFFIm Board reports
9. Report from Audit & Investigations

Consent agenda

1. Delegation of Board Chair Recruitment to Governance Committee
2. Committee Chair appointments
3. Board/Committee member appointments
4. Appointment of Treasurer
5. Evaluation Advisory Committee Terms of Reference
6. Appeals Tribunal
7. Audit & Investigations Terms of Reference
8. Currency Hedging Policy
9. Gavi Evaluation Policy
10. Cold Chain Equipment Optimisation Platform
11. Financial Update
THANK YOU